Affordable Access

deepdyve-link
Publisher Website

Monitoring disease progression with plasma creatinine in amyotrophic lateral sclerosis clinical trials.

Authors
  • van Eijk, Ruben P A1
  • Eijkemans, Marinus J C2
  • Ferguson, Toby A3
  • Nikolakopoulos, Stavros2
  • Veldink, Jan H1
  • van den Berg, Leonard H1
  • 1 Department of Neurology, University Medical Center Utrecht, Utrecht, The Netherlands. , (Netherlands)
  • 2 Department of Biostatistics and Research Support, University Medical Center Utrecht, Utrecht, The Netherlands. , (Netherlands)
  • 3 Biogen Idec, Boston, Massachusetts, USA.
Type
Published Article
Journal
Journal of Neurology Neurosurgery & Psychiatry
Publisher
BMJ
Publication Date
Oct 30, 2017
Identifiers
DOI: 10.1136/jnnp-2017-317077
PMID: 29084868
Source
Medline
Keywords
License
Unknown

Abstract

Plasma creatinine is an inexpensive and easily accessible biomarker that exhibits less variability between patients with ALS over time and is predictive for the patient's functional status, muscle strength and mortality risk. Plasma creatinine may, therefore, increase the power to detect treatment effects and could be incorporated in future ALS clinical trials as potential surrogate outcome.

Report this publication

Statistics

Seen <100 times